Skip to main content

Nurix Therapeutics

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical enterprise headquartered in San Francisco, California. The company focuses on the discovery, development, and commercialization of small molecule immunomodulatory drugs targeting protein degradation pathways for the treatment of cancer and inflammatory diseases. Its proprietary DELigase platform utilizes targeted protein degradation technology to address challenging therapeutic targets. Principal revenue is currently earned through pharmaceutical research collaboration agreements, clinical milestone payments, and licensing royalties. Nurix Therapeutics Inc is publicly listed on the Nasdaq Stock Market.

4 of the funds FundTelligence covers report a position in Nurix Therapeutics.

Legal name
Nurix Therapeutics Inc
Sector
Health Care
Country
United States
Funds holding it
4

Funds holding Nurix Therapeutics

Loading...